Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.
Am J Geriatr Psychiatry. 2003.
PMID: 12611743
Review.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 0 |
Search Results
21 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.
Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):131-45.
Am J Geriatr Psychiatry. 2003.
PMID: 12611743
Review.
Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug Administration (FDA) for treatment of this condition. This review provides evidenced-ba …
Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with Alzheimer disease (AD) and are t …
Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine.
Dement Neurocogn Disord. 2025 Jan;24(1):1-23. doi: 10.12779/dnd.2025.24.1.1. Epub 2025 Jan 20.
Dement Neurocogn Disord. 2025.
PMID: 39944527
Free PMC article.
BACKGROUND AND PURPOSE: This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer's …
BACKGROUND AND PURPOSE: This clinical practice guideline provides evidence-based recommendations for trea …
Clinical Practice Guidelines for Dementia: Recommendations for the Pharmacological Treatment of Behavioral and Psychological Symptoms.
Dement Neurocogn Disord. 2025 Jan;24(1):24-43. doi: 10.12779/dnd.2025.24.1.24. Epub 2025 Jan 20.
Dement Neurocogn Disord. 2025.
PMID: 39944528
Free PMC article.
Effective management of BPSD is essential to support patient and caregiver well-being. This study presents evidence-based clinical practice guidelines for pharmacological treatments of BPSD in dementia, focusing on antipsychotics, antidepressants, cogn …
Effective management of BPSD is essential to support patient and caregiver well-being. This study presents evidence-based c …
Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care.
Eur J Anaesthesiol. 2023 Feb 1;40(2):82-94. doi: 10.1097/EJA.0000000000001769. Epub 2022 Nov 15.
Eur J Anaesthesiol. 2023.
PMID: 36377554
In this first European Society of Anaesthesiology and Intensive Care (ESAIC) guideline on peri-operative management of neuromuscular block, we aim to present aggregated and evidence-based recommendations to assist clinicians provide best medical care and ensu …
In this first European Society of Anaesthesiology and Intensive Care (ESAIC) guideline on peri-operative management of neuromuscular block, …
A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements.
Neurol Ther. 2023 Aug;12(4):1257-1284. doi: 10.1007/s40120-023-00504-6. Epub 2023 Jun 1.
Neurol Ther. 2023.
PMID: 37261607
Free PMC article.
RESULTS: 53 clinical practice guidelines were identified, 15 of which were published since 2018. Screening for asymptomatic populations was not recommended. ...Pharmacologic therapies were not recommended for MCI, while cholinesterase inhibit …
RESULTS: 53 clinical practice guidelines were identified, 15 of which were published since 2018. Screening for asymptomatic po …
Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.
Med J Aust. 2019 Mar;210(4):174-179. doi: 10.5694/mja2.50015. Epub 2019 Feb 16.
Med J Aust. 2019.
PMID: 30771226
INTRODUCTION: Cholinesterase inhibitors (ChEIs) and memantine are medications used to treat the symptoms of specific types of dementia. ...Therefore, appropriate use of ChEIs and memantine involves both prescribing these medications to individuals who are likely to …
INTRODUCTION: Cholinesterase inhibitors (ChEIs) and memantine are medications used to treat the symptoms of specific types of …
Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28. doi: 10.1016/j.amjopharm.2006.10.001.
Am J Geriatr Pharmacother. 2006.
PMID: 17157793
Search terms included Alzheimer's disease, dementia, clinical practice guidelines, clinical trials, screening and assessment, and managed care. ...Recommendations for using these medications are made with an appreciation of the difficulties in translat …
Search terms included Alzheimer's disease, dementia, clinical practice guidelines, clinical trials, screening and asses …
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
Can J Psychiatry. 2002 Oct;47(8):715-22. doi: 10.1177/070674370204700802.
Can J Psychiatry. 2002.
PMID: 12420649
Review.
METHOD: A Medline search was conducted for RCTs, using the following key words: Alzheimer's disease, dementia, therapy, cholinesterase inhibitor, donepezil, rivastigmine, and galantamine. Studies were critically appraised, followed by a review of published major clinica …
METHOD: A Medline search was conducted for RCTs, using the following key words: Alzheimer's disease, dementia, therapy, cholinesterase …
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.
Drugs Aging. 2016 Jul;33(7):451-60. doi: 10.1007/s40266-016-0372-3.
Drugs Aging. 2016.
PMID: 27154396
Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer's disease. This article provides evidence-based recommendations to address the issues regarding the use of cholinest …
Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer' …
Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
Manag Care Interface. 2000 Jan;13(1):51-6.
Manag Care Interface. 2000.
PMID: 10747691
The Alzheimer's Disease Managed Care Advisory Council, a panel of experts from managed care, academic medicine, and the Los Angeles chapter of the Alzheimer's Association was convened to synthesize current evidence-based recommendations for AD diagnostic and …
The Alzheimer's Disease Managed Care Advisory Council, a panel of experts from managed care, academic medicine, and the Los Angeles chapter …
Cite